Edesa Biotech is a biopharmaceutical company developing therapies for inflammatory and immune-related diseases. Its pipeline includes EB06 (anti-CXCL10 monoclonal antibody) for vitiligo, EB01 (daniluromer cream) for allergic contact dermatitis, and EB05 (paridiprubart) for Acute Respiratory Distress Syndrome (ARDS). In October 2025, paridiprubart met primary and secondary endpoints in a Phase 3 ARDS study. The company in-licenses assets from academic institutions and biopharmaceutical companies and pursues government grants and partnerships for development.
Q2 FY2026 — expected 2026-09-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-12-12 | 2025-09-30 | 0001171843-25-007914 | EDGAR | 73K words |
| 2024-12-13 | 2024-09-30 | 0001171843-24-006946 | EDGAR | 70K words |
| 2023-12-15 | 2023-09-30 | 0001654954-23-015632 | EDGAR | 70K words |
| 2022-12-16 | 2022-09-30 | 0001654954-22-016633 | EDGAR | 58K words |
| 2021-12-28 | 2021-09-30 | 0001654954-21-013551 | EDGAR | — |
| 2020-12-07 | 2020-09-30 | 0001654954-20-013236 | EDGAR | — |
| 2018-11-30 | 2018-09-30 | 0001144204-18-062614 | EDGAR | — |
| 2017-12-01 | 2017-09-30 | 0001144204-17-061791 | EDGAR | — |
| 2016-12-14 | 2016-09-30 | 0001144204-16-139528 | EDGAR | — |
| 2015-12-14 | 2015-09-30 | 0001144204-15-070753 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-13 | 2026-06-30 | 0001171843-26-005502 | EDGAR | 20K words |
| 2026-02-13 | 2025-12-31 | 0001171843-26-000812 | EDGAR | 17K words |
| 2025-08-08 | 2025-06-30 | 0001171843-25-005236 | EDGAR | 21K words |
| 2025-05-14 | 2025-03-31 | 0001171843-25-003189 | EDGAR | 21K words |
| 2025-02-14 | 2024-12-31 | 0001171843-25-000866 | EDGAR | 17K words |
| 2024-08-09 | 2024-06-30 | 0001171843-24-004651 | EDGAR | 16K words |
| 2024-05-10 | 2024-03-31 | 0001654954-24-005971 | EDGAR | 16K words |
| 2024-02-09 | 2023-12-31 | 0001654954-24-001540 | EDGAR | 14K words |
| 2023-08-09 | 2023-06-30 | 0001654954-23-010380 | EDGAR | 16K words |
| 2023-05-11 | 2023-03-31 | 0001654954-23-006231 | EDGAR | 14K words |
| 2023-02-10 | 2022-12-31 | 0001654954-23-001577 | EDGAR | 12K words |
| 2022-08-12 | 2022-06-30 | 0001654954-22-011208 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-20 | 0001171843-26-005686 | EDGAR | 26K words |
| 2026-08-13 | 0001171843-26-005499 | EDGAR | 3K words |
| 2026-02-24 | 0001171843-26-001046 | EDGAR | 2K words |
| 2026-02-13 | 0001171843-26-000810 | EDGAR | 2K words |
| 2025-12-12 | 0001171843-25-007918 | EDGAR | 1K words |
| 2025-12-12 | 0001171843-25-007913 | EDGAR | 2K words |
| 2025-10-28 | 0001171843-25-006690 | EDGAR | 1K words |
| 2025-09-30 | 0001171843-25-006188 | EDGAR | 1K words |
| 2025-09-09 | 0001171843-25-005800 | EDGAR | 1K words |
| 2025-08-08 | 0001171843-25-005235 | EDGAR | 3K words |
318 total filings indexed. 286 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001540159 |
| Ticker | EDSA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | A1 |
| Website | https://www.edesabiotech.com |
| Listed | 2010-06-09 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/EDSA (~200 tokens, structured JSON with cryptographic provenance)